Compare Bank of Nova Scotia (BNS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Zimmer Biomet Holdings Inc — how do they compare? Bank of Nova Scotia trades at $89.81 (market cap $108.32B), while Zimmer Biomet Holdings Inc trades at $95.26 (market cap $18.55B). The key difference: Bank of Nova Scotia is far larger — about 5.8× Zimmer Biomet Holdings Inc's market cap, and Bank of Nova Scotia pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| BNS | ZBH | |
|---|---|---|
Market Cap | $108.32B | $18.55B |
Sector | Financials | Health |
52-Week High | $90.29 | $107.71 |
52-Week Low | $56.41 | $79.58 |
Dividend Yield | 3.64% | 0.99% |
Enterprise Value | — | $25.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.56, down 0.33% on the day. The stock exhibits a bullish technical trend with strong analyst support, evidenced by a 'Buy' consensus from 53% of covering analysts. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.47 surpassing the $1.42 estimate. The company maintains a solid net income margin of 24.86% and recently announced a dividend of $1.14 per share, highlighting its commitment to shareholder returns.
The outlook for BNS is positive, supported by earnings momentum, a diversified banking model, and an attractive dividend. Key risks include exposure to macroeconomic volatility and competitive pressures in the banking sector. The current valuation, with a P/E of 17.1, appears reasonable relative to its profitability and growth prospects.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
